Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study
Prostate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This surgical technique, however, has not yet been standardized. We present our findings of using a high-power thulium laser to accomplish vapoenucleation of the pr...
Saved in:
Published in | BMC urology Vol. 15; no. 1; p. 40 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
09.05.2015
BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Prostate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This surgical technique, however, has not yet been standardized. We present our findings of using a high-power thulium laser to accomplish vapoenucleation of the prostate (ThuVEP).
We prospectively collected and analyzed data from 29 patients who underwent ThuVEP between August 2010 and May 2012. The control group included 30 patients who underwent traditional transurethral resection of the prostate (TURP). Operative variables, patient profiles, preoperative and postoperative urine flow rates, prostate volume (measured using transrectal ultrasonography), and the international prostate symptom score (IPSS) were recorded and analyzed using a two-tailed Student's t-test and analysis of variance.
The ages (mean ± SD) of the patients were 76.1 ± 9.4 and 72.6 ± 7.4 years (p = 0.28) in the ThuVEP and TURP groups, respectively. The average urinary flow rates before and 12 months after the operation (volume/maximum flow/average flow) were 243.3/10.5/5.0 and 302.8/17.6/9.4 (in mL, mL/s, mL/s, respectively) in the ThuVEP group and 247.2/10.8/4.6 and 369.9/20.8/12.0, respectively, in the TURP group. Preoperative and postoperative IPSSs were 17.1 ± 5.0 and 6.5 ± 3.8, respectively, in the ThuVEP group and 18.2 ± 4.5 and 6.2 ± 3.3, respectively, in the TURP group. The mean ratio of the estimated postoperative residual prostate volume to the preoperative total volume was 0.47 (p = 0.449) in both groups. The overall complication rate was 20.7% in the ThuVEP group and 30.0% in the TURP group.
One year of follow-up showed that ThuVEP and TURP effectively alleviated subjective and objective voiding symptoms with a low rate of complications. Thus, vapoenucleation using a high-power laser is feasible in elderly patients.
ISRCTN registry with study ID ISRCTN52339705 . Date assigned: 06/03/2015. |
---|---|
AbstractList | Prostate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This surgical technique, however, has not yet been standardized. We present our findings of using a high-power thulium laser to accomplish vapoenucleation of the prostate (ThuVEP). We prospectively collected and analyzed data from 29 patients who underwent ThuVEP between August 2010 and May 2012. The control group included 30 patients who underwent traditional transurethral resection of the prostate (TURP). Operative variables, patient profiles, preoperative and postoperative urine flow rates, prostate volume (measured using transrectal ultrasonography), and the international prostate symptom score (IPSS) were recorded and analyzed using a two-tailed Student's t-test and analysis of variance. The ages (mean [+ or -] SD) of the patients were 76.1 [+ or -] 9.4 and 72.6 [+ or -] 7.4 years (p = 0.28) in the ThuVEP and TURP groups, respectively. The average urinary flow rates before and 12 months after the operation (volume/maximum flow/average flow) were 243.3/10.5/5.0 and 302.8/17.6/9.4 (in mL, mL/s, mL/s, respectively) in the ThuVEP group and 247.2/10.8/4.6 and 369.9/20.8/12.0, respectively, in the TURP group. Preoperative and postoperative IPSSs were 17.1 [+ or -] 5.0 and 6.5 [+ or -] 3.8, respectively, in the ThuVEP group and 18.2 [+ or -] 4.5 and 6.2 [+ or -] 3.3, respectively, in the TURP group. The mean ratio of the estimated postoperative residual prostate volume to the preoperative total volume was 0.47 (p = 0.449) in both groups. The overall complication rate was 20.7% in the ThuVEP group and 30.0% in the TURP group. One year of follow-up showed that ThuVEP and TURP effectively alleviated subjective and objective voiding symptoms with a low rate of complications. Thus, vapoenucleation using a high-power laser is feasible in elderly patients. BACKGROUNDProstate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This surgical technique, however, has not yet been standardized. We present our findings of using a high-power thulium laser to accomplish vapoenucleation of the prostate (ThuVEP).METHODSWe prospectively collected and analyzed data from 29 patients who underwent ThuVEP between August 2010 and May 2012. The control group included 30 patients who underwent traditional transurethral resection of the prostate (TURP). Operative variables, patient profiles, preoperative and postoperative urine flow rates, prostate volume (measured using transrectal ultrasonography), and the international prostate symptom score (IPSS) were recorded and analyzed using a two-tailed Student's t-test and analysis of variance.RESULTSThe ages (mean ± SD) of the patients were 76.1 ± 9.4 and 72.6 ± 7.4 years (p = 0.28) in the ThuVEP and TURP groups, respectively. The average urinary flow rates before and 12 months after the operation (volume/maximum flow/average flow) were 243.3/10.5/5.0 and 302.8/17.6/9.4 (in mL, mL/s, mL/s, respectively) in the ThuVEP group and 247.2/10.8/4.6 and 369.9/20.8/12.0, respectively, in the TURP group. Preoperative and postoperative IPSSs were 17.1 ± 5.0 and 6.5 ± 3.8, respectively, in the ThuVEP group and 18.2 ± 4.5 and 6.2 ± 3.3, respectively, in the TURP group. The mean ratio of the estimated postoperative residual prostate volume to the preoperative total volume was 0.47 (p = 0.449) in both groups. The overall complication rate was 20.7% in the ThuVEP group and 30.0% in the TURP group.CONCLUSIONSOne year of follow-up showed that ThuVEP and TURP effectively alleviated subjective and objective voiding symptoms with a low rate of complications. Thus, vapoenucleation using a high-power laser is feasible in elderly patients.TRIAL REGISTRATIONISRCTN registry with study ID ISRCTN52339705 . Date assigned: 06/03/2015. Prostate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This surgical technique, however, has not yet been standardized. We present our findings of using a high-power thulium laser to accomplish vapoenucleation of the prostate (ThuVEP). We prospectively collected and analyzed data from 29 patients who underwent ThuVEP between August 2010 and May 2012. The control group included 30 patients who underwent traditional transurethral resection of the prostate (TURP). Operative variables, patient profiles, preoperative and postoperative urine flow rates, prostate volume (measured using transrectal ultrasonography), and the international prostate symptom score (IPSS) were recorded and analyzed using a two-tailed Student's t-test and analysis of variance. The ages (mean ± SD) of the patients were 76.1 ± 9.4 and 72.6 ± 7.4 years (p = 0.28) in the ThuVEP and TURP groups, respectively. The average urinary flow rates before and 12 months after the operation (volume/maximum flow/average flow) were 243.3/10.5/5.0 and 302.8/17.6/9.4 (in mL, mL/s, mL/s, respectively) in the ThuVEP group and 247.2/10.8/4.6 and 369.9/20.8/12.0, respectively, in the TURP group. Preoperative and postoperative IPSSs were 17.1 ± 5.0 and 6.5 ± 3.8, respectively, in the ThuVEP group and 18.2 ± 4.5 and 6.2 ± 3.3, respectively, in the TURP group. The mean ratio of the estimated postoperative residual prostate volume to the preoperative total volume was 0.47 (p = 0.449) in both groups. The overall complication rate was 20.7% in the ThuVEP group and 30.0% in the TURP group. One year of follow-up showed that ThuVEP and TURP effectively alleviated subjective and objective voiding symptoms with a low rate of complications. Thus, vapoenucleation using a high-power laser is feasible in elderly patients. ISRCTN registry with study ID ISRCTN52339705 . Date assigned: 06/03/2015. Background Prostate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This surgical technique, however, has not yet been standardized. We present our findings of using a high-power thulium laser to accomplish vapoenucleation of the prostate (ThuVEP). Methods We prospectively collected and analyzed data from 29 patients who underwent ThuVEP between August 2010 and May 2012. The control group included 30 patients who underwent traditional transurethral resection of the prostate (TURP). Operative variables, patient profiles, preoperative and postoperative urine flow rates, prostate volume (measured using transrectal ultrasonography), and the international prostate symptom score (IPSS) were recorded and analyzed using a two-tailed Student's t-test and analysis of variance. Results The ages (mean [+ or -] SD) of the patients were 76.1 [+ or -] 9.4 and 72.6 [+ or -] 7.4 years (p = 0.28) in the ThuVEP and TURP groups, respectively. The average urinary flow rates before and 12 months after the operation (volume/maximum flow/average flow) were 243.3/10.5/5.0 and 302.8/17.6/9.4 (in mL, mL/s, mL/s, respectively) in the ThuVEP group and 247.2/10.8/4.6 and 369.9/20.8/12.0, respectively, in the TURP group. Preoperative and postoperative IPSSs were 17.1 [+ or -] 5.0 and 6.5 [+ or -] 3.8, respectively, in the ThuVEP group and 18.2 [+ or -] 4.5 and 6.2 [+ or -] 3.3, respectively, in the TURP group. The mean ratio of the estimated postoperative residual prostate volume to the preoperative total volume was 0.47 (p = 0.449) in both groups. The overall complication rate was 20.7% in the ThuVEP group and 30.0% in the TURP group. Conclusions One year of follow-up showed that ThuVEP and TURP effectively alleviated subjective and objective voiding symptoms with a low rate of complications. Thus, vapoenucleation using a high-power laser is feasible in elderly patients. Trial registration ISRCTN registry with study ID ISRCTN52339705. Date assigned: 06/03/2015. Keywords: Benign prostate enlargement, Quanta thulium surgical laser system, Thulium laser, Vapoenucleation |
ArticleNumber | 40 |
Audience | Academic |
Author | Chang, Yen-Hwa Huang, William J S Chang, Ching-Hsin Lin, Tzu-Ping Chen, Kuang-Kuo Lin, Alex T L |
Author_xml | – sequence: 1 givenname: Ching-Hsin surname: Chang fullname: Chang, Ching-Hsin email: jossp1029@gmail.com, jossp1029@gmail.com, jossp1029@gmail.com organization: Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan. jossp1029@gmail.com – sequence: 2 givenname: Tzu-Ping surname: Lin fullname: Lin, Tzu-Ping email: tplin63@gmail.com, tplin63@gmail.com, tplin63@gmail.com organization: Shu-Tien Urological Science Research Center, Taipei, Taiwan. tplin63@gmail.com – sequence: 3 givenname: Yen-Hwa surname: Chang fullname: Chang, Yen-Hwa email: yhchang@vghtpe.gov.tw, yhchang@vghtpe.gov.tw, yhchang@vghtpe.gov.tw organization: Shu-Tien Urological Science Research Center, Taipei, Taiwan. yhchang@vghtpe.gov.tw – sequence: 4 givenname: William J S surname: Huang fullname: Huang, William J S email: jshuang@vghtpe.gov.tw, jshuang@vghtpe.gov.tw, jshuang@vghtpe.gov.tw organization: Shu-Tien Urological Science Research Center, Taipei, Taiwan. jshuang@vghtpe.gov.tw – sequence: 5 givenname: Alex T L surname: Lin fullname: Lin, Alex T L email: lin.alextl@gmail.com, lin.alextl@gmail.com, lin.alextl@gmail.com organization: Shu-Tien Urological Science Research Center, Taipei, Taiwan. lin.alextl@gmail.com – sequence: 6 givenname: Kuang-Kuo surname: Chen fullname: Chen, Kuang-Kuo email: kkchen@vghtpe.gov.tw, kkchen@vghtpe.gov.tw, kkchen@vghtpe.gov.tw organization: Shu-Tien Urological Science Research Center, Taipei, Taiwan. kkchen@vghtpe.gov.tw |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25956819$$D View this record in MEDLINE/PubMed |
BookMark | eNptUUtrFTEYDVKxD_0BbiTgxk1q3pNxIZTio1DoproSQmbmy72RTDJOZiz335vLraWFkkXCdx6cfOcUHaWcAKG3jJ4zZvTHwrhpJaFMEUoFJ80LdMJkwwiXLT169D5Gp6X8ppQ1RulX6JirVmnD2hP066ebMqS1j-CWkBPOHi9bwNOcy-IWwGsJaYMd3obNlkz5DuaKrzGsI46uwPypYjUV2YGbsc8x5juyTrgs67B7jV56Fwu8ub_P0I-vX24vv5Prm29XlxfXpFdCL6QTolNDzWaE1L2krnWGcw3O04obYXSnqQLmWOcFk0NjBqnUoCSXg_ROiDP0-eA7rd0IQw9pmV200xxGN-9sdsE-RVLY2k3-a6UURpq9wYd7gzn_WaEsdgylhxhdgrwWy7Thkgut2kp9f6BuXAQbks_Vsd_T7YWSTApaA1fW-TOsegYYQ1_35UOdPxGwg6Cviy8z-If0jNp92fZQtq1l233Ztqmad4-__aD43674B3Gaplk |
CitedBy_id | crossref_primary_10_1097_MD_0000000000030235 crossref_primary_10_1007_s10103_020_03227_4 crossref_primary_10_1016_j_urols_2016_03_006 crossref_primary_10_1016_j_urology_2019_10_022 crossref_primary_10_1002_pros_24717 crossref_primary_10_1007_s00345_021_03704_7 crossref_primary_10_1016_j_juro_2018_05_048 crossref_primary_10_1177_2051415819879667 crossref_primary_10_1186_s12894_019_0437_9 crossref_primary_10_1016_j_urology_2018_09_007 crossref_primary_10_1038_s41391_019_0135_4 crossref_primary_10_1177_1756287216632429 crossref_primary_10_21886_2308_6424_2023_11_4_44_51 crossref_primary_10_3390_life13102077 crossref_primary_10_1007_s11884_021_00627_2 crossref_primary_10_1007_s00345_019_02968_4 crossref_primary_10_1016_j_urols_2016_11_008 crossref_primary_10_2147_CIA_S414799 crossref_primary_10_1007_s00345_021_03825_z |
Cites_doi | 10.1016/j.juro.2009.04.008 10.1016/j.juro.2008.03.058 10.1007/s11255-009-9572-7 10.1111/j.1464-410X.2010.09229.x 10.1097/MOU.0b013e32834120d7 10.1016/S0022-5347(01)63011-8 10.1007/s00345-008-0370-0 10.1097/MOU.0b013e32834100b3 10.1097/MOU.0b013e3283411455 10.1016/j.urology.2008.12.052 10.1002/lsm.20126 10.1111/j.1464-410X.1995.tb07347.x 10.1016/j.juro.2009.11.034 10.1007/s00345-009-0503-0 10.1111/j.1464-410X.2009.08516.x 10.1245/s10434-009-0896-4 10.1016/S0022-5347(05)68186-4 10.1038/sj.ijir.3900401 10.1016/j.eururo.2007.08.036 10.1007/s00345-010-0561-3 10.1111/j.1464-410X.2007.07341.x 10.1007/s00345-010-0522-x 10.1016/j.eururo.2007.05.019 10.1089/end.2005.19.25 10.1111/j.1464-410X.2009.08978.x 10.1007/s00345-007-0171-x |
ContentType | Journal Article |
Copyright | COPYRIGHT 2015 BioMed Central Ltd. Chang et al.; licensee BioMed Central. 2015 |
Copyright_xml | – notice: COPYRIGHT 2015 BioMed Central Ltd. – notice: Chang et al.; licensee BioMed Central. 2015 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1186/s12894-015-0032-7 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2490 |
EndPage | 40 |
ExternalDocumentID | A541430838 10_1186_s12894_015_0032_7 25956819 |
Genre | Randomized Controlled Trial Journal Article Comparative Study |
GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EJD EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX CITATION AFGXO 7X8 5PM |
ID | FETCH-LOGICAL-c536t-b33b5d1788346c40a9a8226eaf05368386b605e1a1bf314d78d455d5424d4fa33 |
IEDL.DBID | RPM |
ISSN | 1471-2490 |
IngestDate | Tue Sep 17 21:23:48 EDT 2024 Sat Oct 05 06:08:23 EDT 2024 Wed Aug 14 18:53:47 EDT 2024 Tue Aug 13 05:21:55 EDT 2024 Thu Sep 12 17:55:50 EDT 2024 Sat Sep 28 08:11:41 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c536t-b33b5d1788346c40a9a8226eaf05368386b605e1a1bf314d78d455d5424d4fa33 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438483/ |
PMID | 25956819 |
PQID | 1682423659 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4438483 proquest_miscellaneous_1682423659 gale_infotracmisc_A541430838 gale_infotracacademiconefile_A541430838 crossref_primary_10_1186_s12894_015_0032_7 pubmed_primary_25956819 |
PublicationCentury | 2000 |
PublicationDate | 2015-May-09 2015-05-09 20150509 |
PublicationDateYYYYMMDD | 2015-05-09 |
PublicationDate_xml | – month: 05 year: 2015 text: 2015-May-09 day: 09 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC urology |
PublicationTitleAlternate | BMC Urol |
PublicationYear | 2015 |
Publisher | BioMed Central Ltd BioMed Central |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
References | 18086107 - BJU Int. 2008 Jan;101(1):131-42 20204378 - World J Urol. 2010 Apr;28(2):163-8 19394500 - Urology. 2009 May;73(5):1042-8 19184038 - World J Urol. 2009 Aug;27(4):541-5 20063164 - World J Urol. 2010 Feb;28(1):45-51 10524887 - J Urol. 1999 Nov;162(5):1640-4 10404287 - Int J Impot Res. 1999 Jun;11(3):177 21099689 - Curr Opin Urol. 2011 Jan;21(1):31-5 17566639 - Eur Urol. 2008 Feb;53(2):382-89 20091426 - Ann Surg Oncol. 2010 May;17(5):1422-8 15735378 - J Endourol. 2005 Jan-Feb;19(1):25-31 9628595 - J Urol. 1998 Jul;160(1):12-6; discussion 16-7 19338541 - BJU Int. 2009 Aug;104(4):434-6 20184573 - BJU Int. 2010 Sep;106(6):822-6 18499179 - J Urol. 2008 Jul;180(1):246-9 19535100 - J Urol. 2009 Aug;182(2):626-32 16405847 - Zhonghua Yi Xue Za Zhi. 2005 Nov 30;85(45):3225-8 15662624 - Lasers Surg Med. 2005 Jan;36(1):52-6 19472910 - Zhonghua Nan Ke Xue. 2009 Apr;15(4):346-9 21099690 - Curr Opin Urol. 2011 Jan;21(1):36-41 19449121 - Int Urol Nephrol. 2010 Mar;42(1):7-12 7537604 - Br J Urol. 1995 Mar;75(3):347-53 21045706 - Curr Opin Urol. 2011 Jan;21(1):42-8 20092844 - J Urol. 2010 Mar;183(3):1105-9 20577744 - World J Urol. 2011 Apr;29(2):211-6 17530258 - World J Urol. 2007 Jun;25(3):257-62 19863522 - BJU Int. 2010 May;105(10):1429-33 17869409 - Eur Urol. 2008 Jan;53(1):160-6 RC Flanigan (32_CR4) 1998; 160 T Bach (32_CR16) 2007; 25 Q Shao (32_CR17) 2009; 15 T Bach (32_CR24) 2010; 28 SJ Xia (32_CR19) 2008; 53 C Jeldres (32_CR7) 2009; 182 M Morgan (32_CR27) 2009; 104 A Descazeaud (32_CR28) 2011; 29 RJ Hoekstra (32_CR5) 2010; 106 E Gnessin (32_CR12) 2011; 21 KL Lo (32_CR1) 2010; 42 P Gilling (32_CR21) 2008; 101 RM Kuntz (32_CR11) 2008; 53 PJ Gilling (32_CR9) 1999; 162 J Placer (32_CR13) 2009; 73 O Reich (32_CR8) 2008; 180 G Robert (32_CR3) 2011; 21 SJ Xia (32_CR18) 2005; 85 NM Fried (32_CR14) 2005; 19 RM Merrill (32_CR2) 2010; 17 JE Oesterling (32_CR20) 1995; 75 RD Smith (32_CR23) 2011; 21 NM Fried (32_CR15) 2005; 36 T Bach (32_CR26) 2009; 27 AE Krambeck (32_CR10) 2010; 183 N Masumori (32_CR6) 2010; 105 JA Vroege (32_CR22) 1999; 11 TR Herrmann (32_CR25) 2010; 28 |
References_xml | – volume: 182 start-page: 626 year: 2009 ident: 32_CR7 publication-title: J Urol doi: 10.1016/j.juro.2009.04.008 contributor: fullname: C Jeldres – volume: 180 start-page: 246 year: 2008 ident: 32_CR8 publication-title: J Urol doi: 10.1016/j.juro.2008.03.058 contributor: fullname: O Reich – volume: 42 start-page: 7 year: 2010 ident: 32_CR1 publication-title: Int Urol Nephrol doi: 10.1007/s11255-009-9572-7 contributor: fullname: KL Lo – volume: 106 start-page: 822 year: 2010 ident: 32_CR5 publication-title: BJU Int doi: 10.1111/j.1464-410X.2010.09229.x contributor: fullname: RJ Hoekstra – volume: 21 start-page: 31 year: 2011 ident: 32_CR12 publication-title: Curr Opin Urol doi: 10.1097/MOU.0b013e32834120d7 contributor: fullname: E Gnessin – volume: 160 start-page: 12 year: 1998 ident: 32_CR4 publication-title: J Urol doi: 10.1016/S0022-5347(01)63011-8 contributor: fullname: RC Flanigan – volume: 27 start-page: 541 year: 2009 ident: 32_CR26 publication-title: World J Urol doi: 10.1007/s00345-008-0370-0 contributor: fullname: T Bach – volume: 21 start-page: 42 year: 2011 ident: 32_CR3 publication-title: Curr Opin Urol doi: 10.1097/MOU.0b013e32834100b3 contributor: fullname: G Robert – volume: 21 start-page: 36 year: 2011 ident: 32_CR23 publication-title: Curr Opin Urol doi: 10.1097/MOU.0b013e3283411455 contributor: fullname: RD Smith – volume: 85 start-page: 3225 year: 2005 ident: 32_CR18 publication-title: Zhonghua Yi Xue Za Zhi contributor: fullname: SJ Xia – volume: 73 start-page: 1042 year: 2009 ident: 32_CR13 publication-title: Urology doi: 10.1016/j.urology.2008.12.052 contributor: fullname: J Placer – volume: 36 start-page: 52 year: 2005 ident: 32_CR15 publication-title: Lasers Surg Med doi: 10.1002/lsm.20126 contributor: fullname: NM Fried – volume: 75 start-page: 347 year: 1995 ident: 32_CR20 publication-title: Br J Urol doi: 10.1111/j.1464-410X.1995.tb07347.x contributor: fullname: JE Oesterling – volume: 183 start-page: 1105 year: 2010 ident: 32_CR10 publication-title: J Urol doi: 10.1016/j.juro.2009.11.034 contributor: fullname: AE Krambeck – volume: 28 start-page: 45 year: 2010 ident: 32_CR25 publication-title: World J Urol doi: 10.1007/s00345-009-0503-0 contributor: fullname: TR Herrmann – volume: 104 start-page: 434 year: 2009 ident: 32_CR27 publication-title: BJU Int doi: 10.1111/j.1464-410X.2009.08516.x contributor: fullname: M Morgan – volume: 17 start-page: 1422 year: 2010 ident: 32_CR2 publication-title: Ann Surg Oncol doi: 10.1245/s10434-009-0896-4 contributor: fullname: RM Merrill – volume: 162 start-page: 1640 year: 1999 ident: 32_CR9 publication-title: J Urol doi: 10.1016/S0022-5347(05)68186-4 contributor: fullname: PJ Gilling – volume: 11 start-page: 177 year: 1999 ident: 32_CR22 publication-title: Int J Impot Res doi: 10.1038/sj.ijir.3900401 contributor: fullname: JA Vroege – volume: 53 start-page: 160 year: 2008 ident: 32_CR11 publication-title: Eur Urol doi: 10.1016/j.eururo.2007.08.036 contributor: fullname: RM Kuntz – volume: 29 start-page: 211 year: 2011 ident: 32_CR28 publication-title: World J Urol doi: 10.1007/s00345-010-0561-3 contributor: fullname: A Descazeaud – volume: 101 start-page: 131 year: 2008 ident: 32_CR21 publication-title: BJU Int doi: 10.1111/j.1464-410X.2007.07341.x contributor: fullname: P Gilling – volume: 28 start-page: 163 year: 2010 ident: 32_CR24 publication-title: World J Urol doi: 10.1007/s00345-010-0522-x contributor: fullname: T Bach – volume: 53 start-page: 382 year: 2008 ident: 32_CR19 publication-title: Eur Urol doi: 10.1016/j.eururo.2007.05.019 contributor: fullname: SJ Xia – volume: 15 start-page: 346 year: 2009 ident: 32_CR17 publication-title: Zhonghua Nan Ke Xue contributor: fullname: Q Shao – volume: 19 start-page: 25 year: 2005 ident: 32_CR14 publication-title: J Endourol doi: 10.1089/end.2005.19.25 contributor: fullname: NM Fried – volume: 105 start-page: 1429 year: 2010 ident: 32_CR6 publication-title: BJU Int doi: 10.1111/j.1464-410X.2009.08978.x contributor: fullname: N Masumori – volume: 25 start-page: 257 year: 2007 ident: 32_CR16 publication-title: World J Urol doi: 10.1007/s00345-007-0171-x contributor: fullname: T Bach |
SSID | ssj0017856 |
Score | 2.18214 |
Snippet | Prostate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This surgical... Background Prostate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This... BACKGROUNDProstate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This surgical... |
SourceID | pubmedcentral proquest gale crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 40 |
SubjectTerms | Age Factors Aged Aged, 80 and over Analysis Follow-Up Studies Humans Laser Therapy - methods Lasers in medicine Lasers, Solid-State - therapeutic use Male Prospective Studies Prostatic Hyperplasia - complications Prostatic Hyperplasia - diagnosis Prostatic Hyperplasia - surgery Risk Assessment Severity of Illness Index Sex Factors Thulium Time Factors Transurethral Resection of Prostate - methods Treatment Outcome Urinary Bladder Neck Obstruction - etiology Urinary Bladder Neck Obstruction - physiopathology Urinary Bladder Neck Obstruction - surgery Urinary Retention - etiology Urinary Retention - physiopathology Urinary Retention - surgery |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3rS90wFA9OYezLmO51nUoGg8Egm2keTQciIooI7tPu8MMg5NE4wbX13ls2__ud0_aqHSL02ylNOI_kd5qT3yHkg_fSG51yFrzPIUGJnjmeItNIvi_xh3LA-85n3_TJVJ6eq_MVsmxvNShw_mBqh_2kprOrz3-vb_Yh4Pe6gDf6yxzWWCS45YqBjwJgfELWMgmJOlbyybtDhdyo_rJRzhlkHctDzgc_Mdqm_l-s7-1W40rKe1vT8QvyfMCU9KB3gnWyUlYb5OnZcGr-kvz84Zq6rJC5uLMDrRMF3EcbvPEBWJNi8fsFdRS5i1mDfdNA3l5dtr8pgOty9hVkdVWyGwgLmsBz6j-sbWhHTfuKTI-Pvh-esKGrAgtK6AXzQngVQRlGSB3kriscgARdugTxqI0w2kOKU3LHfRJcxtxEqVRUMpNRJifEa7JawZhvCXUyJMhIYgoAYzgWTAF6UbEIXBdZ2FUT8mmpRNv05Bm2SzqMtr3GLWgc6Ukzm0_IR1SzRVODLoMb7gfAUEhRZQ-wYbkAxGgmZGv0JgREGInfLw1lUYRVZFVZt3PLtUH4qFUxIW96w93OC9JA5GIDST4y6e0LyMM9llSXvzo-bimFkUZsPj6td-RZ1vkXPMUWWV3M2nIbAM3C73Ru-g9MSPAb priority: 102 providerName: Scholars Portal |
Title | Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25956819 https://search.proquest.com/docview/1682423659 https://pubmed.ncbi.nlm.nih.gov/PMC4438483 |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9RAEB7aCuIX8d1oPVYQBGF7ze1LNn5rS0sRrpRi5RBh2ZdED3pJaC-I_96ZXFIufhTCfpmEhNknu8_szjwL8MF76Y0uMx68zzBAiZ67tIxck_i-pAXlQPXO8wt9fi2_LNRiB9RQC9Ml7Qe_PKhuVgfV8leXW9mswnTIE5tezk-kFEYaMd2FXQToEKL3WweZUbrfvkyNnt7hAEzqt6niCGBkkyT_q6hIjsR1tuaif0fkrSlpnC65Nf-cPYHHPXFkR5sPfAo7RfUMHs77rfHn8OOba-qiInniztmsLhmSO9ZQWQcSSkYZ7j-ZYyRQzBs6HA3t7c2yXTFk0MXtZ7TVVcH_IPZZifCof_O2YZ3-7Au4Pjv9enLO-6MTeFBCr7kXwquIvjBC6iAPXe6QCejClfjTaSOM9hjHFKlLfSlSGTMTpVJRyZmMsnRCvIS9Ct_5GpiTocSwI5YBuUpKWVFIUVTMQ6rzWThUCXwanGibjUKG7SILo-3G-RadTxqkM5sl8JHcbOnvQV8G1xcB4KtIh8oe0ankAmmhSWB_dCeiPozM74eOsmSiVLGqqNs7m2pDHFGrPIFXm467_66h4xPIRl16fwOJbY8tiMFOdLvH3Jv_fvItPJp1KMQr34e99W1bvENCs_YThPEim8CD49OLy6tJtyyA7VwabK-Ov086gP8F7en5_A |
link.rule.ids | 230,315,730,783,787,867,888,24330,27936,27937,31732,33757,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB9qBe2L3x_RqisIgrB3l9uPbHwrxXJqr_jQlj4Iy-4m0aO9JLQXRP96Z_JR7vqmkLdJ2CTzm-xvsjO_BXjnvfRGFwkP3ieYoGSeu7jIuCbxfUk_lAP1O8-P9OxEfjlTZ1ughl6Ytmg_-MWovFiOysXPtrayXobxUCc2_jbfl1IYacT4FtzGeJ3IIUnvFw8So3S_gBkbPb7CTzDp38aKI4SRT5IAsKI2OZLXWZuNbn6T1yalzYLJtRno4D6cDvfeFZ6cj5qVH4U_N2Qd__nhHsC9npOyvc78ELby8hHcmfer7o_h-6mrq7wk5ePWj6wqGPJGVlPHCHJVRsXzP5hjpH3Ma9p3De3NxaJZMiTn-eVHtFVlzn9jWLECkVf94k3NWmnbJ3By8Ol4f8b7XRl4UEKvuBfCqwxfshFSBzlxqUOSoXNXYDxrI4z2mCLlsYt9IWKZJSaTSmVKTmUmCyfEU9guccznwJwMBWY0WRGQBsVUcIXsR2VpiHU6DRMVwYfBO7buxDdsm7QYbTuvWvQqyZtObRLBe_KfpcBEJwXX9xfgUCRxZfdow3OBjNNEsLtxJgZU2DC_HRBgyURVaGVeNVc21obop1ZpBM86RFzf14CoCJINrFyfQDremxZEQKvn3Xv8xX9f-Qbuzo7nh_bw89HXl7AzbaGOR7oL26vLJn-FvGnlX7dR8hc8_Bak |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9RAEF-0QvGL9VmjVVcQBCGXy-0jG7-V6lEfV_rBShFh2UdWD3tJaC8U_eudyaNc-rGQb7Nhk8zM7m-yM78h5I213CoZsthZm0GA4m1s0uBjieT7HH8oO6x3XhzJwxP--VScbrT6apP2nV1OyrPVpFz-bnMr65VLhjyx5HhxwDlTXLGk9iG5Te6Az07lEKj3BwiZErI_xEyVTC5gGUYO3FTEYMaAKZEEWGCpHFLsbOxI19fljY1pnDS5sQvNd8iP4fm75JM_k2ZtJ-7fNWrHG73gfXKvx6Z0vxvygNwqyodke9Gfvj8iP7-buipKZEBu9UmrQAE_0horRwCzUkyi_0UNRQ7kuMb-ayBvzpbNigJIL87fg6wqi_gvuBcNYIHVZdzUtKW4fUxO5h-_HRzGfXeG2Akm17FlzAoPH1oxLh2fmtwA2JCFCeDXUjElLYRKRWpSG1jKfaY8F8ILPuOeB8PYE7JVwpxPCTXcBYhsfHAAh1JMvAIUJHzuUpnP3FRE5N2gIV13JBy6DV6U1J1mNWgWaU5nOovIW9ShRgcFRTnT1xnAVEh1pfex8TkD5KkisjcaCY7lRuLXgxVoFGE2WllUzYVOpUIYKkUekd3OKq6ea7CqiGQje7kagHzeYwlYQcvr3Wv92Y3vfEW2jz_M9ddPR1-ek7uz1trhyvfI1vq8KV4AfFrbl62j_AcDaxkk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vapoenucleation+of+the+prostate+using+a+high-power+thulium+laser%3A+a+one-year+follow-up+study&rft.jtitle=BMC+urology&rft.au=Chang%2C+Ching-Hsin&rft.au=Lin%2C+Tzu-Ping&rft.au=Chang%2C+Yen-Hwa&rft.au=Huang%2C+William+JS&rft.date=2015-05-09&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2490&rft.eissn=1471-2490&rft.volume=15&rft_id=info:doi/10.1186%2Fs12894-015-0032-7&rft.externalDocID=A541430838 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2490&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2490&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2490&client=summon |